Januvia reduces nocturnal hypoglycemia in T2D - Merck
Merck has announced results from a post-hoc analysis of Phase III data showing that patients with Type 2 Diabetes having treatment intensified with insulin glargine therapy while also being treated with Januvia (sitagliptin) 100 mg once-daily had a lower incidence of nocturnal hypoglycemia compared to patients also receiving placebo. The study was conducted over 24 weeks in 660 insulin-treated patients.
Starting two weeks after randomization, patients were to increase their dose of insulin every three days to reach a targeted fasting blood sugar level of 72-100 mg/dL. After 24 weeks, patients randomized to Januvia received less additional insulin compared to patients randomized to placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins